Comparison on the Clinical Effects and Safety of Different Doses of Rivaroxaban in the Treatment of Elderly Patients with Heart Failure Complicated with Atrial Fibrillation
Objective To compare the clinical effects and safety of different doses of rivaroxaban in the treatment of elderly patients with heart failure(HF)complicated with atrial fibrillation(AF).Methods A total of 80 elderly patients with HF complicated with AF admitted to our hospital from January 2020 to January 2022 were selected and randomly and equally divided into two groups.On the basis of routine treatment,the control group was treated with 20 mg/d rivaroxaban,and the study group was treated with 10 mg/d rivaroxaban.The coagulation function,cardiac function and adverse events were compared between the two groups.Results After 1 month of treatment,the coagulation function indicators(D-D,PT)and cardiac function indicators(NT-proBNP,LVEF)of the two groups were significantly improved compared with those before treatment(P<0.05),while no statistical difference was found between the two groups(P>0.05).Within 6 months of follow-up,the incidence of adverse events in the study group was 7.50%,significantly lower than 25.00%in the control group(P<0.05).Conclusions 10 mg/d dose of rivaroxaban and 20 mg/d dose of rivaroxaban in the treatment of elderly patients with HF complicated with AF have equivalent effect,which can effectively improve coagulation function and cardiac function,but the incidence of adverse events of 10 mg/d dose is lower.
Different dosesRivaroxabanHeart failureAtrial fibrillationCoagulation functionCardiac functionAdverse event
国家科技期刊平台
NSTL
万方数据
维普
